Wenyang Huoxue Jiedu formula inhibits thin-cap fibroatheroma plaque formation via the VEGF/VEGFR signaling pathway.

@article{Chen2018WenyangHJ,
  title={Wenyang Huoxue Jiedu formula inhibits thin-cap fibroatheroma plaque formation via the VEGF/VEGFR signaling pathway.},
  author={Shuang Xiu Chen and Zi-qing Ye and Zhi-Wen Li and Chun-Xiao Zhao and Guang-Jin Chen and Jun-Zhuo Zhou and Chuan Ping Wang and Rui-Li Huang and Yong-Dun Hong},
  journal={Journal of ethnopharmacology},
  year={2018},
  volume={219},
  pages={213-221}
}
ETHNOPHARMACOLOGICAL RELEVANCE For many years, Guangzhou University of Chinese Medicine has been successfully using the empirical Wenyang Huoxue Jiedu formula (WHJF) to treat coronary heart disease. Modern theories of acute coronary syndrome mainly focus on rupture of thin-cap fibroatheromas (TCFAs), which is closely related to the release of vascular endothelial growth factor and its receptor (VEGF/VEGFR). AIM OF STUDY We investigated the effects of WHJF on the formation of TCFA plaques and… CONTINUE READING